Drug Approval | December 31, 2022
USFDA grants appeal for Ardelyx's XPHOZAH
Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism
Upon approval, XPHOZAH would be the first and only phosphate absorption inhibitor, offering patients a novel mechanism
The current approval is first of the many fillings made by the company's CDMO partners from the flagship facility in Bangalore
Her previous role at Novartis, where she was general manager, data & digital, in global drug development, also included accountability for driving the DCT strategy, programs and platforms
CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.
This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled study
LG Chem will receive totaling up to $95.5 million for the China rights
To focus on providing safer burn treatments for women and armed forces
He has global experience in strategic and operational leadership including at Board, CEO and Senior Corporate levels
Implants from the U.S. startup Allay Therapeutics are designed to relieve pain after knee surgery for up to three weeks
The new center will focus on supporting the clinical trials clients who are developing cell and gene therapies
Subscribe To Our Newsletter & Stay Updated
